Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Slides:

Advertisements

Similar presentations

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Quality of Life After Treatment of Laryngeal.

Advertisements

Volume 42, Issue 5, Pages (May 2005)

Triangles and dotted lines are for mean values. , P <

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Psychosocial Correlates of Symptoms in Functional Dyspepsia

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Clinical Epidemiology and Global Health

Marlene H. Frost, RN, PhD, Amy E. Bonomi, MPH, PhD, Joseph C

Lung Resection Improves the Quality of Life of Patients With Symptomatic Bronchiectasis Camilla Carlini Vallilo, MS, Ricardo Mingarini Terra, MD, PhD,

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

Volume 61, Issue 5, Pages (November 2014)

The Impact of Pain Management on Quality of Life

Postoperative pain after abdominal hysterectomy: a randomized, double-blind, controlled trial comparing continuous infusion vs patient-controlled intraperitoneal.

Effects of deep hypothermic circulatory arrest on outcome after resection of ascending aortic aneurysm Franz F Immer, MD, Hanna Barmettler, MD, Pascal.

Baseline Comorbidity Associated With the Short-Term Effects of Exercise Intervention on Quality of Life in the Japanese Older Population: An Observational.

Health-Related Quality of Life Outcome After On-Pump Versus Off-Pump Coronary Artery Bypass Graft Surgery: A Prospective Randomized Study Reza Motallebzadeh,

Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,

Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,

Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity Nina K. Grewal,

Long-Term Health-Related Quality of Life After Maze Surgery for Atrial Fibrillation Catharina Lundberg, MD, Anders Albåge, MD, PhD, Carina Carnlöf, RN,

Laila Hellgren, MD, Elisabeth Ståhle, MD, PhD

Comparison of recovery after mitral valve repair and replacement

Mu Qin et al. JACEP 2017;j.jacep

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Frequency of patients in flare at each time point over 3 months

Clinical Epidemiology and Global Health

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

Health-Related Quality of Life in Patients Attending a Gastroenterology Outpatient Clinic: Functional Disorders Versus Organic Diseases Magnus Simrén,

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

The Journal of Allergy and Clinical Immunology: In Practice

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Clinical response in patients with early and established RA at month 24. *p

Least squares mean (LSM) changes from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total score and (B) Ankylosing.

Patient-reported quality of life after abdominal aortic aneurysm surgery: A prospective comparison of endovascular and open repair Badr Aljabri, MD,

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Percentage of patients with RA achieving DAS28(CRP)<2

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment Ralf W. Sprengers, MD, Martin Teraa,

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Multivariable analysis of Clinical Disease Activity Index (CDAI) over time modelled with a cubic effect of time and adjusted for age, gender, disease duration,

Quality of life after aortic valve replacement with tissue and mechanical implants Artyom Sedrakyan, MD, Patricia Hebert, PhD, Viola Vaccarino, MD, PhD,

J. J. Smith, FRCS, A. M. Garratt, PhD, M. Guest, FRCS, R. M

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

LPA groups display vastly different outcomes.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Presentation transcript:

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA and (C) 24 weeks in SUMMACTA. The MCID for PROs were defined as follows: HAQ-DI: ≥0.22; PtGA: ≥10; patient pain: ≥10; FACIT-Fatigue: ≥4; SF-36 PCS/MCS: ≥2.5; and SF-36 domains: ≥5.0. Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA and (C) 24 weeks in SUMMACTA. The MCID for PROs were defined as follows: HAQ-DI: ≥0.22; PtGA: ≥10; patient pain: ≥10; FACIT-Fatigue: ≥4; SF-36 PCS/MCS: ≥2.5; and SF-36 domains: ≥5.0. Analyses were performed using the intention-to-treat population in OPTION (TCZ-intravenous, n=205; PBO, n=204), intention-to-treat population in BREVACTA (TCZ-subcutaneous, n=437; PBO, n=219) and per-protocol population in SUMMACTA (TCZ-subcutaneous, n=558; TCZ-intravenous, n=537). *P<0.05; **P<0.01; ***P<0.001. BP, bodily pain; FACIT, Functional Assessment of Chronic Illness Therapy; GH, general health; HAQ-DI, Health Assessment Questionnaire-Disability Index; IV, intravenous; MCID, minimum clinically important difference; MCS, mental component score; MH, mental health; PBO, placebo; PCS, physical component score; PF, physical functioning; PtGA, patient global assessment; qw, weekly; q2w, every 2 weeks; q4w, every 4 weeks; RE, role-emotional; RP, role-physical; SC, subcutaneous; SF, social functioning; SF-36, Short Form-36; TCZ, tocilizumab; VT, vitality. Vibeke Strand et al. RMD Open 2018;4:e000602 Copyright © BMJ Publishing Group & EULAR. All rights reserved.